The Invention policy is based on the following References.
![thesiliconreview-dr-mehmet-ali-soylemez-founder-söylemez-investment-2024-psd.jpg](https://thesiliconreview.com/story_image_upload/us/thesiliconreview-dr-mehmet-ali-soylemez-founder-s%C3%B6ylemez-investment-2024-psd.jpg)
Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS. More than 49 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS of healthcare. Please see the papers…
Molecular Therapy 11:S346-S346 · May 2005. AMERICAN SOCIETY OF GENE THERAPY 8th Annual Meeting • June 1 – 5, 2005 • St. Louis, MISSOURI, UNITED STATES OF AMERICA. DOI: https://doi.org/10.1016/j.ymthe.2005.07.437
Molecular Therapy 13:S86-S86 · May 2006. AMERICAN SOCIETY OF GENE THERAPY 9th Annual Meeting •, BALTIMORE, MARYLAND. UNITED STATES OF AMERICA. DOI: https://doi.org/10.1016/j.ymthe.2006.08.250
3- Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome.
Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. J Clin Endocrinol Metab. 2010 Sep;95(9):E26-31. doi: 10.1210/jc.2010-0305. Epub 2010 Jun 9.
4- Plasma procalcitonin and risk of type 2 diabetes in the general population.
Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. Diabetologia. 2011 Sep;54(9):2463-5. DOI: 10.1007/s00125-011-2216-3.
Mutluoğlu M, Uzun G, İpcioğlu OM, Sildiroglu O, Özcan Ö, Turhan V, Mutlu H, Yildiz S.Diabetes Res Clin Pract. 2011 Oct;94(1):53-6. doi:10.1016/j.diabres.2011.05.023. Epub 2011 Jun 11.
Chen B, Niu YW, Xie T, Miao MY, Tian M, Ji XY, Qing C, Lu SL. Zhonghua Shao Shang Za Zhi. 2011 Apr;27(2):139-44.
Benjamin A Lipsky 1, Anthony R Berendt, Paul B Cornia, James C Pile, Edgar J G Peters, David G Armstrong, H Gunner Deery, John M Embil, Warren S ; Infectious Diseases Society of America Clin Infect Dis 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346
8- Plasma procalcitonin and the risk of cardiovascular events: A prospective population-based study.
J Intern Med 2012;272(5):484-91. Schiopu A, Hedblad B, Engström G, Struck J, Morgenthaler NG, Melander O.
9- 25-OH-Vitamin D and procalcitonin levels after correction of acute hyperglycemia.
Aksu NM1, Aksoy DY, Akkaş M, Yilmaz H, Akman C, Yildiz BO, Ozmen MM, Usman A.Med Sci Monit. 2013 Apr 12;19:264-8. doi: 10.12659/MSM.883880.
Saeed K, Ahmad N, Dryden M. Expert Rev Mol Diagn. 2014 Jan;14(1):47-54. doi: 10.1586/14737159.2014.864238. Epub 2013 Dec 2. Review. PMID:24308337.
11- Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers?
Int J Endocrinol Metab. 2014 Jan 5;12(1):e13376. doi: 10.5812/ijem.13376. eCollection 2014 Jan. Nematollah Jonaidi Jafari 1, Mahdi Safaee Firouzabadi 1, Morteza Izadi 1, Mohammad Sadegh Safaee Firouzabadi 2, Amin Saburi 3
12- Higher procalcitonin level in diabetic nephropathy patients compared with healthy volunteers].
Wan ZM, Chen WY, Lu ML, Zhou HT, Gao YL, Zhang C, Han G, Tang XL, Huang XD.Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 May;45(3):442-6. PMID:24941814.
13- Recent Advances in Detection of AGEs: Immunochemical, Bioanalytical and Biochemical Approaches
Jalaluddin Mohd.Ashraf et al.., IUBMB Life 2015 Dec;67(12):897-913. doi: 10.1002/iub.1450. Epub 2015 Nov 23.
14– Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27).
Landman GW, et al., Atherosclerosis. 2016 Jul;250:46-51. doi: 10.1016/j.atherosclerosis.2016.04.015. Epub 2016 Apr 27.
15– The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis.
Victoria van Asten SA, et al., Curr Diabetes Rev. 2016;12(4):396-402.
16- ASSOCIATION OF SERUM PROCALCITONIN (PCT) and HIGH-SENSITIVITY C-REACTIVE PROTEIN (hs-CRP) LEVELS with INSULIN RESISTANCE and OBESITY in TYPE 2 EGYPTIAN DIABETIC PATIENTS.
AYAT I. GHANEM and MOHSEN KHALID, M.D. Med. J. Cairo Univ. Vol.84, No.1, September: 1165-1171, 2016.
Al-Shammaree SAW et al., J Res Med Sci. 2017 Aug 16;22:95. doi: 10.4103/jrms.JRMS_906_16. eCollection 2017.
18– Concentration of acute phase factors in vitreous fluid in diabetic macular edema.
Kimura K, Orita T, Kobayashi Y, Matsuyama S, Fujimoto K, Yamauchi K. Jpn J Ophthalmol. 2017 Nov;61(6):479-483. doi: 10.1007/s10384-017-0525-x. Epub 2017 Jul 28.
19- Role of procalcitonin in infected diabetic foot ulcer.
Park JH, etal.,Diabetes Res Clin Pract. 2017 Jun;128:51-57. doi: 10.1016/j.diabres.2017.04.008. Epub 2017 Apr 13.
20– Procalcitonin as a Biomarker for Predicting Amputation Level in Lower Extremity Infections.
Reiner MM,et al.,J Foot Ankle Surg. 2017 May – Jun;56(3):484-491. doi: 10.1053/j.jfas.2017.01.014. Epub 2017 Mar 22.
Pichu S, et al.,Biomark Med. 2017 Apr;11(4):377-388. doi: 10.2217/bmm-2016-0205. Epub 2017 Mar 14. Review.
22– The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis.
Van Asten SA, et al., Int Wound J. 2017 Feb;14(1):40-45. doi: 10.1111/iwj.12545. Epub 2015 Dec 3.
23- The role of procalcitonin as a marker of diabetic foot ulcer infection.
Massara M, et al., Int Wound J. 2017 Feb;14(1):31-34. doi: 10.1111/iwj.12536. Epub 2015 Oct 28.
Umapathy D etal., J Vasc Surg. 2018 Apr;67(4):1283-1291.e2. doi: 10.1016/j.jvs.2017.02.060. Epub 2017 Jul 21.
Shatha Abdul Wadood AL-Shammaree et al., J Res Med Sci. 2017; 22: 95. PMC5583618.
HANAA H AHMED et al., Asian Journal of Pharmaceutical and clinical research (AJPCR) VOL 10 ISSUE 9 SEPTEMBER 2017 297-306. Research Article. https://doi.org/10.22159/ajpcr.2017.v10i9.19524.
27- [АNALYSIS OF LETHALITY IN COMPLICATED DIABETIC FOOT SYNDROME AND SEPSIS]
O V Тrybushnyi, S D Shapoval, I L Savon, V Novak Klin Khir. 2017;(1):58-60.
28- Procalcitonin and proinflammatory parameters in diabetic foot infection as new predictive factor .
Shler Gh. Raheem 1, Ruqaya M. Al-Barzinji, Husham Y. Mansoor and Ali A. Al-Dabbagh ; Department of Microbiology and Department of Surgery, Hawler Medical University, IRAQ 6th International Conference and Workshops on Basic and Applied SciencesAIP Conf. Proc.1888, 020043-1–020043-9; https://doi.org/10.1063/1.5004320
Velissaris D et al., Rom J Intern Med. 2018 Mar 1;56(1):3-8. doi: 10.1515/rjim-2017-0039.
30- Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population.
Suthahar N1, Meijers WC1, Brouwers FP1, Heerspink HJL2, Gansevoort RT3, van der Harst P1, Bakker SJL3, de Boer RA4.Int J Cardiol. 2018 Jan 1;250:188-194. doi: 10.1016/j.ijcard.2017.10.035. Epub 2017 Oct 16.
Open Access Maced J Med Sci. 2018 Aug 20; 6(8): 1349–1353. Ghada M. El Kassas,1 Manal A. Shehata,1,* Maged A. El Wakeel,1 Ahmed F. Amer,1 Fatma A. Elzaree,1 Marwa K. Darwish,2 and Marwa F. Amer3
32- Moderate increase of serum levels of procalcitonin in diabetic ketoacidosis.
Neth J Med. 2018 Dec;76(10):454. A Cipriano 1, E Rebelos, N Park, M Santini
33- Serum procalcitonin levels as a biomarker for diagnosis of gestational diabetes mellitus
Süleyman Baldane, Süleyman Hilmi İpekci, Ayşegül Kebapcılar, Sedat Abuşoğlu, Bahadır Öztürk, Ali Ünlü, Çetin Çelik, Levent Kebapcılar. Selçuk Üniversitesi Tıp Fakültesi; İç Hastalıkları Anabilim Dalı, Endokrinoloji ve Metabolizma Hastalıkları Bilim Dalı, KONYA, TURKEY. Cukurova Medical Journal 2018;43(1):62-66 https://doi.org/10.17826/cumj.340258
34- Redefined clinical spectra of diabetic foot syndrome.
Nawaf J Shatnawi 1, Nabil A Al-Zoubi 1, Hasan Hawamdeh 2, Yousef S Khader 3, Abd El-Karim Omari 1, Muhammad R Khammash . Vasc Health Risk Manag. 2018 Oct 18;14:291-298. doi: 10.2147/VHRM.S169502.
Adlyne R Asirvatham 1, Usha Menon 2, Praveen V Pavithran 2, Jayakumar R Vasukutty 3, Harish Kumar 2, Nisha Bhavani 2, Arun Menon 2, Vasantha Nair 2, Vivek Lakshmanan 2, Ajit K Varma 4, Mangalanandan T Sukumaran 2, Arun Bal 2 Indian J Endocrinol Metab. Jan-Feb 2019;23(1):122-127. doi: 10.4103/ijem.IJEM_525_18.
Anno T, Shigemoto R, Kawasaki F et al, Diabetes Metab. 2019 Jun 4. pii: S1262-3636(19)30089-8. doi: 10.1016/j.diabet.2019.05.006.
Ma Y, Ye W, Tang Y.Medicine ; Baltimore, MARYLAND, UNITED STATES Of AMERICA. 2019 Mar;98(11):e14914. doi: 10.1097/MD.0000000000014914.
38- Predictive value of procalcitonin for infection of patients with type-2 diabetes mellitus.
Exp Ther Med 2019 Jul;18(1):722-728. doi: 10.3892/etm.2019.7611. Epub 2019 May 24. Xinshui Wang,1,* Yanbei Sun,2,* and Xiaonan Shao3
Arch Acad Emerg Med. 2019 Jul 10;7(1):37. eCollection 2019. Fahimeh Hadavand 1, Atefeh Amouzegar 2, Hessam Amid 1
Journal of Diabetes Research Volume 2019, Article ID 4312737, 5 pages https://doi.org/10.1155/2019/4312737 Marco Meloni,1 Valentina Izzo,1 Laura Giurato,1 Enrico Brocco,2 Michele Ferrannini,3 Roberto Gandini,4 and Luigi Uccioli1,2
41- Serum Procalcitonine level in diabetic foot patients.
Nature and Science 2019;17(11) Sama Fathy Mohamed , Nashwa Mohamed Aboalnasr1, Loai Mohamed El-Ahwal, Mamdouh Radwan El-Nahas ,Saharmohey El-Din Hazzaa. Department of internal medicine and Pathology, Tanta University, Faculty of Medicine, EGYPT.
Aslan S, Demirdal T, Erbak H, Aslan C. Infect Dis (Lond). 2020 Feb;52(2):107-113. doi:10.1080/23744235.2019.1688387. Epub 2019 Nov 12.PMID: 31713451
43- Elevation of serum procalcitonin (sPCT) in a non-infected patient:
diabetes mellitus as a neglected cause of high sPCT values:
Minerva Anestesiologica 2020 April;86(4):465-6 DOI: 10.23736/S0375-9393.19.14180-6 Chiara ROBINO 1 *,Christian A. COMPAGNONE, Federico POZZI, Francesco CURTO, Arturo CHIEREGATO
44- The predictive value of procalcitonin for early detection of infection in elderly type 2 diabetes mellitus.
J Infect Chemother 2020 Apr;26(4):343-348. doi:10.1016/j.jiac.2019.10.015. Epub 2019 Nov 15. Wei Lin 1, Huibin Huang 1, Junping Wen 1, Gang Chen 1, Xingsheng Lin 2, Songchang Shi 3
45- [Diabetic foot syndrome] [Article in German]
Lea Slahor 1, Lukas Iselin 2 Ther Umsch. 2020 Sep;77(7):339-346. doi: 10.1024/0040-5930/a001201
Intern Med 2020 Nov 23. doi: 10.2169/internalmedicine.5841-20. Shohei Fukunaga 1, Yuki Hoshino 1, Hirotaka Sonoda 1, Miharu Kawanishi 1, Asuka Yamauchi 1, Shiho Kato 1, Kaori Yoshikane 1, Hiroaki Shiina 2, Kazuaki Tanabe 1, Takafumi Ito 1
47- An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage.
Yuqing Wang 1, Tengteng Shao 1, Jialin Wang 1, Xiaoting Huang 1, Xiaofei Deng 2, Yemin Cao 2, Mingmei Zhou 3, Cheng Zhao 4 Biomed Pharmacother. 2021 Jan;133:110991. doi:10.1016/j.biopha.2020.11099 1.
Zahra Soleimani 1, Fatemeh Amighi 2 et al.., Hum Antibodies .2021;29(2):115-121. doi: 10.3233/HAB-210439.
49- The efficacy of inflammatory markers in diagnosing infected diabetic foot ulcers and diabetic foot osteomyelitis: Systematic review and meta-analysis.
Harman Sharma 1, Sandhli Sharma 2, et al.., . http://Meta-Analysis PLoS One . 2022 Apr 27;17(4):e0267412. doi: 10.1371/journal.pone.0267412. eCollection 2022.
50- A Study of Association of Plasma Procalcitonin with Various Components of Metabolic Syndrome and Insulin Resistance.
Aditya Vyas 1, Prakash Keswani 1, Shrikant Sharma 1, et al., Observational Study J Assoc Physicians India .2022 Apr;70(4):11-12.